GPCM
LEGN icon

Granite Point Capital Management’s Legend Biotech LEGN Stock Holding History

Granite Point Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$426K – 182
2020
Q2 		$426K Buy
+10,000
New +$391K 0.02% 133

Other funds holding LEGN

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Granite Point Capital Management's LEGN Position: Q3 2020 in Review

Granite Point Capital Management sold out of Legend Biotech (LEGN) in Q3 2020, closing a stake of 10,000 shares — an estimated $426K sold.

Granite Point Capital Management first reported a position in LEGN in Q2 2020 and held it in 1 quarter. The position peaked at $426K in Q2 2020. 50 funds tracked by Wall St. Rank hold LEGN as of Q3 2020.

  • Granite Point Capital Management reported no remaining Legend Biotech position as of Q3 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 10,000 Legend Biotech shares in Q3 2020, an estimated $426K.
  • Granite Point Capital Management first reported a position in Legend Biotech in Q2 2020 and held it in 1 quarter.
  • Granite Point Capital Management's Legend Biotech position peaked at $426K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2020.

Based on Granite Point Capital Management's 13F filing for Q3 2020, filed 6 Nov 2020.